A 2026 review outlines the shift in solid organ transplantation from broad immunosuppression to Treg-based active tolerance. It covers polyclonal Tregs, CAR-Tregs and CRISPR-edited off-the-shelf products.
A seminar will present work on KRAS-driven lung cancer and immunotherapy resistance. The research uses immune-competent mouse models and CRISPR-Cas9 screens to identify targets that sensitise tumour cells to T cell-mediated killing.
Scientists have developed two breakthrough approaches to dramatically enhance gene editing and mRNA therapy delivery: a simple amino acid supplement that increases CRISPR efficiency to nearly 90 percent, and a self-replicating CRISPR system that spreads between cells like a virus.
Researchers unveil tumor-intrinsic role of PD-L1 in lung cancer progression and develop systematic method for discovering molecular glues that selectively degrade disease proteins, while advances in immunology research aim to improve care for immune-mediated inflammatory diseases.
Transposase systems are emerging as efficient alternatives to CRISPR-Cas9 for gene editing in biopharmaceutical manufacturing and plant breeding, with studies showing up to 90% efficiency and heritability rates while offering advantages in size and integration capabilities.
The global biotechnology market is undergoing a transformation from discovery-based science to precision engineering, driven by AI, synthetic biology, and gene editing technologies, with projected growth of 13-15% over the next five years.
The global CRISPR and prime editing market is forecast to grow at 24.1% CAGR through 2031, driven by therapeutic advances and regulatory progress. Scribe Therapeutics achieved a second milestone with Eli Lilly, while new RNA production and gene editing technologies accelerate research.
